Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Keymed Biosciences's Enterprise Value is €2,396.72 Mil.
Keymed Biosciences's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was €-61.05 Mil. Therefore, Keymed Biosciences's EV-to-EBIT ratio for today is -39.26.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Keymed Biosciences's Enterprise Value is €2,396.72 Mil.
Keymed Biosciences's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was €-49.19 Mil. Therefore, Keymed Biosciences's EV-to-EBITDA ratio for today is -48.72.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Keymed Biosciences's Enterprise Value is €2,396.72 Mil.
Keymed Biosciences's Revenue for the trailing twelve months (TTM) ended in Dec. 2025 was €86.60 Mil. Therefore, Keymed Biosciences's EV-to-Revenue ratio for today is 27.68.
*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.
Keymed Biosciences (FRA:64Z) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Keymed Biosciences's current Enterprise Value is €2,396.72 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Keymed Biosciences's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was €-61.05 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Keymed Biosciences's current Enterprise Value is €2,396.72 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Keymed Biosciences's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was €-49.19 Mil.
Keymed Biosciences's current Enterprise Value is €2,396.72 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Keymed Biosciences's Revenue for the trailing twelve months (TTM) ended in Dec. 2025 was €86.60 Mil.
Keymed Biosciences's current Enterprise Value is €2,396.72 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Keymed Biosciences's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was €-86.29 Mil.
Keymed Biosciences's current Enterprise Value is €2,396.72 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Keymed Biosciences's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was €-127.01 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Keymed Biosciences Enterprise Value Related Terms
Keymed Biosciences Enterprise Value Historical Data
* Premium members only.
The historical data trend for Keymed Biosciences's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:64Z vs VRTX, REGN, RVMD: Enterprise Value Comparison
For the Biotechnology subindustry, Keymed Biosciences's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Keymed Biosciences Enterprise Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Keymed Biosciences's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Keymed Biosciences's Enterprise Value falls into.
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Keymed Biosciences's Enterprise Value for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Enterprise Value of €2,396.72 Mil mean?
Keymed Biosciences (FRA:64Z) has a Enterprise Value of €2,396.72 Mil as of Aug. 06, 2026. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Keymed Biosciences and its competitors.
Is Keymed Biosciences' Enterprise Value too high?
Keymed Biosciences' current Enterprise Value is €2,396.72 Mil. Overall, Keymed Biosciences has a GF Score™ of 44/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Keymed Biosciences' Enterprise Value compare to VRTX and REGN?
Keymed Biosciences' Enterprise Value of €2,396.72 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Enterprise Value for a Biotechnology company?
A good Enterprise Value depends on the Biotechnology industry context. However, Enterprise Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Enterprise Value mean?
A high Enterprise Value can signal that a stock is expensive relative to its fundamentals. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Keymed Biosciences and its competitors. Keymed Biosciences's current Enterprise Value is €2,396.72 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Keymed Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Keymed Biosciences (FRA:64Z) is currently considered Possible Value Trap. The stock's GF Value™ is €18.50, compared to a current price of €8.45 — trading 54.3% below its estimated fair value. The current Enterprise Value is €2,396.72 Mil. Keymed Biosciences' overall GF Score™ is 44/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Enterprise Value calculated?
Enterprise Value is calculated from a company's financial statements. For Keymed Biosciences (FRA:64Z), the current Enterprise Value is €2,396.72 Mil as of Aug. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Keymed Biosciences (FRA:64Z) Overvalued in 2026?
Based on GuruFocus' analysis, Keymed Biosciences stock appears to be undervalued.
The current stock price of €8.45 is trading 54.3% below its estimated GF Value™ of €18.50.
GuruFocus considers Keymed Biosciences to be Possible Value Trap.
Key valuation signals for FRA:64Z:
Enterprise Value: €2,396.72 Mil
GF Value™: €18.50 vs. price of €8.45 (54.3% below fair value)
No single metric tells the full story. See the FRA:64Z stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Keymed Biosciences Inc is a biotechnology company with multiple clinical-stage assets. The company is focused on the in-house discovery and development of biological therapies that address large underserved medical needs in the autoimmune and oncology therapeutic areas. Its clinical-stage drug candidates include CM310, CM326, CM313, and CM336 among others. The company is engaged in biopharmaceutical research and development, which is regarded as a single reportable segment. Geographically, it generates a majority of its revenue from overseas markets and the rest from Mainland China.
44GF Score
Get the complete analysis for FRA:64Z
Enterprise Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:64Z has been successfully added to your 
